---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-24-000014"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:18:05.433129+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B

## Summary
- Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.
- GAAP EPS $6.10; non-GAAP adjusted EPS $18.29, vs. $13.20 in 2022.
- Key growth drivers: Xywav +33%, Epidiolex +15%, Rylaze +40% in 2023.
- 2024 guidance: revenue $4.0-4.2B, non-GAAP adjusted EPS $18.15-19.35.
- Oncology revenue surpassed $1B in 2023; $161M remains for share buybacks.

## SEC filing metadata
- accession: 0001232524-24-000014
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/0001232524-24-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/jazz-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-24-000014
- JSON: https://secwatch.observer/filing/0001232524-24-000014.json
- Plain text: https://secwatch.observer/filing/0001232524-24-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.